ArticleScientific reports2025
Travel distance may have a negative impact on the outcome of deep brain stimulation in Parkinson's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Potential beneficial effects of teleprogramming on the efficacy of deep brain stimulation (DBS) have not been studied. We aimed to explore the effects of travel distance on the outcome of DBS in Parkinson's disease (PD). We retrospectively analyzed travel- and visit-related data of PD patients treated with DBS. Comparing the first-year and five-year outcomes of far-living patients (> 50 km) having the desired number of follow-up visits (n = 74) to those of far-living subjects having less visits than optimal (n = 54), patients with desired number of visits had better global health-related quality of life according to summary indexes of disease-specific and non-specific scales at five years. Far-living patients with desired number of visits had larger decrease in Parts II, III and IV of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale from baseline to the five-year follow-up and more simplified antiparkinsonian medication treatment. Even 40% of PD patients with DBS who live far from the movement disorder center may have less in-person visits than optimal and be on the risk of having worse long-term outcome of DBS than could be achieved. Teleprogramming may help maintaining the long-term efficacy of stimulation in this group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.